jackson_tai

Banker joins Lilly Board

pharmafile | October 25, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing jackson tai, lilly 

Eli Lilly has appointed ex-investment banker Jackson Tai to its Board to serve on the Audit and Finance Committee from November.

Tai is currently a non-executive director of The Bank of China Limited, Singapore Airlines, NYSE Euronext, MasterCard Incorporated, and Royal Philips NV.

From 2002 to 2007 he was vice chairman and chief executive of both DBS Group Holdings and DBS Bank, one of the largest financial services groups in Asia.

Advertisement

I am delighted to welcome Jack Tai to the Lilly board,” said John Lechleiter, Lilly’s chairman, president and chief executive. “Mr Tai brings to the Lilly board extensive experience in international business and finance, including serving as the CEO of a major multinational financial institution and as a board member of several leading global companies.”

Prior to his appointment at DBS Tai was an investment banker for 25 years with J.P. Morgan.

 

Related Content

NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE

BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …

Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …

The Gateway to Local Adoption Series

Latest content